About this trial
The goal of this study is to learn about the impact of an integrated medication monitoring system in breast cancer survivors aged 21-70 who are prescribed endocrine therapy. The main question it aims to address is: Does the integrated medication monitoring system improve medication adherence among breast cancer survivors when used over a six-month period?
Fifteen English-speaking breast cancer survivors who meet the inclusion criteria will use a combination of smartphone-based ecological momentary assessments, a medication event monitoring system (Wisepill), and a wearable sensor (Fitbit). After 2 months, participants will be provided personalized content to facilitate medication adherence through an app (Digital Trails) and through WisePill. Participants will complete online surveys at baseline, 3 months, and 6 months to assess their experiences and adherence.
Eligibility criteria
Qualifiers
are English-speaking and reading;
are between ages 21 and 70 years;
are diagnosed with stage 0-3 breast cancer in the past 5 years;
have completed all surgery, radiation, and chemotherapy, except endocrine therapy;
Disqualifiers
None
Trial design
Treatments tested in this trial
- integrated medication monitoring (MM) system
Treatment groups
Sponsors and collaborators
San Diego State University
Lead sponsor
University of Virginia
Collaborator
National Cancer Institute (NCI)
Collaborator